CLINICAL ROLE -
Combination Therapy Shows Promise in Lung Cancer
Durvalumab and tremelimumab demonstrated antitumor activity in patients with non-small cell lung cancer regardless of PD-L1 status.
Read More
Lung Cancer Combination Therapy Shows Promise